Copolymer 1 data

New data presented at the meeting of the American Neurological Association in Washington, D.C. showed reduced relapse rates, extended time to first relapse, and slowed progression of disability.

In data collected for up to 35 months in 203 patients (of the 251 who participated in the two-year, Phase III trial, the reduction in relapse rate was 32 percent compared to placebo. ...